StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3059% below fair value
$3.44−0.23 (-6.13%)

Close on Nov 20, 2026Market cap $208.32MP/E –Yield –

Vanda Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vanda Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $229.28M, up 8.1% year over year. For fiscal 2025 it was $216.11M, up 8.7% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $268.68M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$216.11M+8.7%
FY2024Dec 31, 2024$198.77M+3.2%
FY2023Dec 31, 2023$192.64M-24.3%
FY2022Dec 31, 2022$254.38M-5.3%
FY2021Dec 31, 2021$268.68M+8.3%
FY2020Dec 31, 2020$248.17M+9.2%
FY2019Dec 31, 2019$227.19M+17.6%
FY2018Dec 31, 2018$193.12M+17.0%
FY2017Dec 31, 2017$165.08M+13.1%
FY2016Dec 31, 2016$146.02M+32.8%
FY2015Dec 31, 2015$109.93M+119.2%
FY2014Dec 31, 2014$50.16M+48.0%
FY2013Dec 31, 2013$33.88M+3.5%
FY2012Dec 31, 2012$32.73M+4.7%
FY2011Dec 31, 2011$31.27M-12.4%
FY2010Dec 31, 2010$35.71M+685.2%
FY2009Dec 31, 2009$4.55M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$69.82M+24.1%
Q2 FY2026Jun 30, 2026$50.53M-3.9%
Q1 FY2026Mar 31, 2026$51.72M+3.4%
Q4 FY2025Dec 31, 2025$57.22M+7.6%
Q3 FY2025Sep 30, 2025$56.26M+18.1%
Q2 FY2025Jun 30, 2025$52.59M+4.2%
Q1 FY2025Mar 31, 2025$50.04M+5.4%
Q4 FY2024Dec 31, 2024$53.19M+17.5%
Q3 FY2024Sep 30, 2024$47.65M+22.8%
Q2 FY2024Jun 30, 2024$50.47M+9.6%
Q1 FY2024Mar 31, 2024$47.46M-24.1%
Q4 FY2023Dec 31, 2023$45.27M-29.8%
Q3 FY2023Sep 30, 2023$38.82M-40.6%
Q2 FY2023Jun 30, 2023$46.06M-28.5%
Q1 FY2023Mar 31, 2023$62.50M+3.8%
Q4 FY2022Dec 31, 2022$64.48M-5.2%
Q3 FY2022Sep 30, 2022$65.32M-6.8%
Q2 FY2022Jun 30, 2022$64.39M-5.2%
Q1 FY2022Mar 31, 2022$60.19M-4.0%
Q4 FY2021Dec 31, 2021$68.02M+0.5%
Q3 FY2021Sep 30, 2021$70.10M+16.2%
Q2 FY2021Jun 30, 2021$67.90M+9.2%
Q1 FY2021Mar 31, 2021$62.67M+8.1%
Q4 FY2020Dec 31, 2020$67.65M+11.0%
Q3 FY2020Sep 30, 2020$60.31M+1.4%
Q2 FY2020Jun 30, 2020$62.21M+5.3%
Q1 FY2020Mar 31, 2020$58.00M+21.6%
Q4 FY2019Dec 31, 2019$60.93M+14.9%
Q3 FY2019Sep 30, 2019$59.49M+21.1%
Q2 FY2019Jun 30, 2019$59.06M+24.7%
Q1 FY2019Mar 31, 2019$47.71M+9.5%
Q4 FY2018Dec 31, 2018$53.04M+19.8%
Q3 FY2018Sep 30, 2018$49.14M+18.9%
Q2 FY2018Jun 30, 2018$47.35M+12.6%
Q1 FY2018Mar 31, 2018$43.59M+16.5%
Q4 FY2017Dec 31, 2017$44.28M+15.8%
Q3 FY2017Sep 30, 2017$41.34M–
Q2 FY2017Jun 30, 2017$42.06M–
Q1 FY2017Mar 31, 2017$37.42M–
Q4 FY2016Dec 31, 2016$38.24M–

More Vanda Pharmaceuticals figures

See a number that looks wrong?